These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 12072335

  • 1. Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients.
    Teebken OE, Strüber M, Harringer W, Pichlmaier MA, Haverich A.
    Transplant Proc; 2002 Jun; 34(4):1265-8. PubMed ID: 12072335
    [No Abstract] [Full Text] [Related]

  • 2. Histopathological findings in heart transplant patients under tacrolimus-mycophenolate mofetil versus cyclosporine microemulsion-azathioprine.
    Sgrosso JL, Ferrer J, Araujo G, Romeo L, Parisi C, Vázquez MC.
    Transplant Proc; 2002 Feb; 34(1):115-6. PubMed ID: 11959214
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The value of routine monitoring of mycophenolic acid plasma levels after clinical heart transplantation.
    Hesse CJ, Vantrimpont P, van Riemsdijk-van Overbeeke IC, van Gelder T, Balk AH, Weimar W.
    Transplant Proc; 2001 May; 33(3):2163-4. PubMed ID: 11377487
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roth D, Kupin W, Nicolas M, Ruiz P, Rosen A, Miller J.
    Transplantation; 2004 Jan 27; 77(2):244-51. PubMed ID: 14742989
    [Abstract] [Full Text] [Related]

  • 8. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
    Guethoff S, Meiser BM, Groetzner J, Eifert S, Grinninger C, Ueberfuhr P, Reichart B, Hagl C, Kaczmarek I.
    Transplantation; 2013 Feb 27; 95(4):629-34. PubMed ID: 23423270
    [Abstract] [Full Text] [Related]

  • 9. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression.
    Mehra MR, Uber PA, Scott RL, Park MH.
    Transplantation; 2002 Dec 15; 74(11):1568-73. PubMed ID: 12490790
    [Abstract] [Full Text] [Related]

  • 10. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
    Zucker MJ, Baran DA, Arroyo LH, Goldstein DJ, Neacy C, Mele L, Weinberg AD, Prendergast TW, Ribner HS.
    Transplant Proc; 2005 Jun 15; 37(5):2231-9. PubMed ID: 15964386
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels.
    Meiser BM, Pfeiffer M, Schmidt D, Ueberfuhr P, Reichenspurner H, Paulus D, von Scheidt W, Kreuzer E, Seidel D, Reichart B.
    Transplant Proc; 1999 Jun 15; 31(1-2):84-7. PubMed ID: 10083018
    [No Abstract] [Full Text] [Related]

  • 13. Tolerability of mycophenolate mofetil in organ transplant recipients.
    Schweizer RT, Meisterling LD.
    Transplant Proc; 2001 May 15; 33(3):2309. PubMed ID: 11377540
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of mycophenolate mofetil in different dosages in Asian renal allograft recipients.
    Tsang WK, Tong KL, Yeung S, Lee W, Chan HW.
    Transplant Proc; 2000 Nov 15; 32(7):1755-6. PubMed ID: 11119921
    [No Abstract] [Full Text] [Related]

  • 17. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection.
    Yamani MH, Starling RC, Goormastic M, Van Lente F, Smedira N, McCarthy P, Young JB.
    Transplantation; 2000 Jun 15; 69(11):2326-30. PubMed ID: 10868634
    [Abstract] [Full Text] [Related]

  • 18. One and a half years of experience with mycophenolate mofetil (Cellcept) in cardiac transplantation: a prospective, randomized study.
    Seebacher G, Weigel G, Griesmacher A, Mallinger R, Zuckermann A, Grimm M, Laufer G.
    Transplant Proc; 1999 Dec 15; 31(8):3291-3. PubMed ID: 10616480
    [No Abstract] [Full Text] [Related]

  • 19. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
    Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, van Veldhuisen P, Salm K, Tolzman D, Fitzsimmons WE.
    Transplantation; 2000 Mar 15; 69(5):834-41. PubMed ID: 10755536
    [Abstract] [Full Text] [Related]

  • 20. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW.
    Clin Transplant; 1997 Aug 15; 11(4):299-312. PubMed ID: 9267719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.